Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? - Wikidata - awgldk - TriplyDB

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

http://www.wikidata.org/entity/Q36335694

about

Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options Colistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health Perspectives Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways.Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HO-1 pathway.Significant accumulation of polymyxin in single renal tubular cells: a medicinal chemistry and triple correlative microscopy approach.Autophagy regulates colistin-induced apoptosis in PC-12 cells.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Carbapenemase-producing Enterobacteriaceae.Polymyxin B Nephrotoxicity: From Organ to Cell Damage.Host-dependent Induction of Transient Antibiotic Resistance: A Prelude to Treatment Failure.Site-specific activity of the acyltransferases HtrB1 and HtrB2 in Pseudomonas aeruginosa lipid A biosynthesis Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells.Species-Dependent Blood-Brain Barrier Disruption of Lipopolysaccharide: Amelioration by Colistin In Vitro and In Vivo Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.Acinetobacter baumannii Isolated from Lebanese Patients: Phenotypes and Genotypes of Resistance, Clonality, and Determinants of Pathogenicity.Altered Outer Membrane Transcriptome Balance with AmpC Overexpression in Carbapenem-Resistant Enterobacter cloacae Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases).Speculative strategies for new antibacterials: all roads should not lead to Rome.Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Treatment option for sepsis in children in the era of antibiotic resistance.Effects of polymyxin-B on TNF-α production in equine whole blood stimulated with three different bacterial toxins.Colistin: still a lifesaver for the 21st century?Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Lipopeptides as therapeutics: applications and in vivo quantitative analysis.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Low-dose polymyxin: an option for therapy of Gram-negative sepsis.

P2860

Q26751255-CC5C3617-0C0C-4D15-B640-B4BA3063F694 Q26991886-5260D81D-7ED5-45FE-8A5E-FD54E5FF8692 Q27015109-11D7367B-EDDF-46B9-A60D-36BB45F76FF6 Q28076261-6BC1F572-B97C-40B0-8A89-3AEFE5DF2E54 Q28082546-D7EE7243-8F12-4184-A97E-CD5301873390 Q33686940-4793E5BD-2A07-4832-8096-AEE8A0899E2A Q33798324-C955AD1C-90CC-425D-A54E-46DD77816785 Q34346283-9B7B250A-3010-425D-906D-AC4713A64A12 Q34552966-F515E760-CC5A-4BFF-9951-072C6EF32087 Q34922961-9C18C813-A92D-41B6-AE25-53901E89FA60 Q35054109-CF8BCE0D-15C7-47A3-8CF9-7223E6F5630C Q35169023-9E45805A-FEFE-411E-AFAD-426A2FF6F2AB Q35617587-8FF027F9-14F7-41D9-BF2C-C4265F1D7771 Q35751615-37F387FF-9696-42D4-87FA-1E3A738DC3F7 Q36105647-663DB92F-3E17-4765-9119-6A3F8C53D44A Q36106267-7B9F80FE-A5E9-4BA0-B8B8-FC57D0778686 Q36226493-E642584D-1CF4-4F4B-9706-C1CE4404AD08 Q36240813-2A7AF4A7-E4F9-4362-B0C2-76EA9FD72230 Q36363261-1C0EAF1F-8EC8-4B1C-BE96-23C9C7144941 Q36642374-24E8BF8A-B0FB-476D-986E-26DEF35AE9AF Q36761826-64E04AD2-B7CB-4538-8C58-73A81117C885 Q37023227-0840F116-E51E-47CB-90C6-71998A614632 Q37124019-A72438C1-3DD2-44A7-821F-517E7D55BF78 Q37124122-015F96AE-233C-4BDF-8C74-E3655D10E80B Q37146405-20D56A07-4F67-4F30-9461-2E1F66A99D41 Q37169946-FE84E562-F59B-4FC5-AAD2-EC711F3388F6 Q37438110-943DC9D9-130A-4CF0-A558-7C7C440DECDE Q37528489-C64303F1-EAE9-482A-96A6-69184B47B99C Q37538748-93EB6B4E-A00F-42D0-B121-262C0373183B Q37562099-705EEBC9-22D9-42C8-965F-B0246939AF90 Q38074212-4B33F9E0-FC34-4896-8AA7-A8C690F63E04 Q38101243-57984C0C-37E0-4D11-A869-B0EE21FA0662 Q38186636-1E04BDCD-052F-40A8-A3BA-D33B4B545641 Q38246118-891661EF-76A4-4A53-A00A-B549E36E67AC Q38626464-36C827B4-396D-4355-BC97-BB863D9529CC Q38940249-E35148F2-F42F-4EAA-B1B2-87E9A5CD9A88 Q38944862-0E93C964-4FB3-4EAA-A4C8-F319E3EC4D95 Q39037677-20E13F92-C61B-43CC-A345-ED0F13EF3B6B Q39333751-F4115E9B-8B89-4C9A-8A58-89E9DD6ECE6D Q40272427-B7DEDED9-29E7-481E-945C-60AFDBF2A062

P2860

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

http://www.wikidata.org/entity/Q36335694

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

@ast

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

@en

type

label

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

@ast

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

@en

prefLabel

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

@ast

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

@en

P1433

Q36335694-AB243127-89A2-477B-8992-98DEA5C643F5

P1476

Q36335694-96C6D85E-09A9-407F-8FFE-8AF8896E7360

P2093

Q36335694-1E28F180-3B67-4904-AE83-927F74A214C8

Q36335694-26D16319-EB3E-4033-87A0-6720A8570807

Q36335694-56D67E4C-5ACD-476C-B03E-6CF1140ED169

Q36335694-B9675FED-5B87-4477-97D4-940B9FDA5DF4

Q36335694-FBE7AA17-1115-475C-B5A0-9E17C385595A

P2860

Q36335694-03CAB2DF-7817-4A0F-A8F5-5F15576BDE44

Q36335694-0409E465-32C3-4289-BA46-B12993E95FE6

Q36335694-08199E0D-F8A6-4578-816E-5A1040E10A4C

Q36335694-0873FA84-71ED-43B9-B8B0-6DBC9A8281D8

Q36335694-089BA8B0-7AEE-436B-886F-EA78E0888541

Q36335694-08D4D18A-6C6A-4651-9406-108C3CF5D7AA

Q36335694-09412386-3F49-427F-9713-3A3ED57F7CB2

Q36335694-0F145EF9-B607-4DE1-91A6-CF34E17A7933

Q36335694-0F561425-6124-4243-AA67-82FD1610B56F

Q36335694-125C490D-DAB8-41B1-BD5E-F979B037F66C

P304

Q36335694-83E6E087-3480-42DD-A846-2FA3A83770AA

P31

Q36335694-89A2F949-ABCD-45D2-87C1-87A35926C7D0

P356

Q36335694-5207169E-445A-434A-90E2-60E865EC9602

P433

Q36335694-645154DD-C504-4350-B9CA-959864893307

P478

Q36335694-B4B97A81-6938-4715-A139-2F2A6BA87593

P50

Q36335694-28B158EE-011A-401B-9BF3-660730304EF7

Q36335694-D7F83FF4-390E-4CFF-95E7-84765152BBF4

P577

Q36335694-16F0BCD6-7841-48D7-9118-3C6F58465CC3

P5875

Q36335694-4D58D205-6B8D-4C53-8AB8-CABB7E881CAC

P698

Q36335694-AF1F1BF3-28F1-49D8-AD57-B55A52A4613D

P932

Q36335694-9240AAC4-8F7B-4031-9B88-B3320313B205

P356

J.DIAGMICROBIO.2012.07.010

P1433

Diagnostic Microbiology and Infectious Disease

P1476

Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?

@en

P2093

Hee Ji Lee

http://www.w3.org/2001/XMLSchema#string

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Miao Zhao

http://www.w3.org/2001/XMLSchema#string

Phillip J Bergen

http://www.w3.org/2001/XMLSchema#string

Roger L Nation

http://www.w3.org/2001/XMLSchema#string

P2860

Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India

Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration

Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

Polymyxins: Antimicrobial susceptibility concerns and therapeutic options

Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS

Drugs for bad bugs: confronting the challenges of antibacterial discovery

Isolation and structural characterization of colistin components.

Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis.

P304

213-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DIAGMICROBIO.2012.07.010

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Cornelia Barbara Landersdorfer

P577

2012-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230837178

http://www.w3.org/2001/XMLSchema#string

P698

22959816

http://www.w3.org/2001/XMLSchema#string

P932

3477253

http://www.w3.org/2001/XMLSchema#string